Journal of Cardiovascular Disease Research

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 9, 2021

Effectiveness of lifestyle interventions versus pharmacological treatments in managing GDM and reducing the risk of complications – A comparative study

Dr. B. Lalitha Devi[1], Dr. G. Radha Rani[2*]

[1]Assistant Professor, Department of Obstetrics and Gynaecology, Nootan Medical College and Research Centre – 384315, India

[2]Assistant Professor, Department of Obstetrics and Gynaecology, Nootan Medical College and Research Centre – 384315, India

[*] **Corresponding author email id: radharani0102@gmail.com**

Abstract:

Introduction: Gestational Diabetes Mellitus (GDM) presents a significant health concern for pregnant individuals globally, with implications for maternal and fetal health. Management strategies for GDM include lifestyle interventions and pharmacological treatments, each offering distinct advantages and considerations. Understanding the comparative effectiveness of these approaches is essential for optimizing GDM management protocols and improving maternal-fetal outcomes. This study aims to compare the effectiveness of lifestyle interventions versus pharmacological treatments in managing GDM and reducing the risk of complications.

Methods: A retrospective comparative study was conducted, including 100 pregnant women diagnosed with GDM, with 50 patients allocated to each treatment group. Participants were recruited from obstetric clinics at a tertiary care hospital. Lifestyle intervention involved personalized counseling sessions focusing on dietary modifications, exercise regimens, and weight management. Pharmacological treatment comprised standard medical therapy with insulin or oral hypoglycemic agents. Baseline characteristics, maternal outcomes (glycemic control, maternal weight gain, hypertensive disorders), and fetal outcomes (birth weight, Apgar scores, neonatal hypoglycemia, NICU admission rates) were assessed and compared between the two groups.

Results: Baseline characteristics were comparable between groups. The lifestyle intervention group demonstrated improved glycemic control, lower incidence of hypertensive disorders, and reduced maternal weight gain compared to the pharmacological treatment group. Infants born to mothers in the lifestyle intervention group had lower birth weight, decreased incidence of neonatal hypoglycemia, and lower NICU admission rates.

Conclusion: This study underscores the importance of adopting a multifaceted approach to GDM management, emphasizing the integration of lifestyle modifications as first-line therapy. By optimizing maternal glycemic control and reducing the risk of pregnancy-related complications, lifestyle interventions have the potential to enhance the quality of care provided to pregnant individuals with GDM and improve the health outcomes of both mothers and offspring.

Introduction :

Gestational Diabetes Mellitus (GDM) represents a significant health concern affecting pregnant women worldwide [1]. Characterized by elevated blood sugar levels during pregnancy, GDM not only poses immediate risks to the health of the mother and fetus but also increases the likelihood of long-term complications for both [2]. In recent years, the

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 9, 2021

management of GDM has been a subject of considerable research and clinical focus, with various approaches being explored to mitigate its impact on maternal and fetal health.

Among the diverse strategies employed in GDM management, lifestyle interventions, and pharmacological treatments stand out as primary modalities. Lifestyle interventions encompass dietary modifications, increased physical activity, and weight management, aiming to control blood sugar levels through non-pharmacological means [3]. Conversely, pharmacological treatments involve the use of medications such as insulin or oral hypoglycemic agents to regulate glucose levels when lifestyle modifications alone are insufficient [4].

Understanding the comparative effectiveness of these two approaches is crucial for optimizing GDM management protocols and improving maternal-fetal outcomes. Therefore, this study seeks to examine the effectiveness of lifestyle interventions versus pharmacological treatments in managing GDM and reducing the risk of complications.

With the rising prevalence of GDM globally, there is a pressing need to identify the most effective and safest approaches for its management. Clinicians must weigh the benefits and risks of lifestyle interventions and pharmacological treatments to tailor treatment plans that optimize maternal and fetal health outcomes [5]. GDM management requires a multifaceted approach that considers not only glycemic control but also maternal and fetal well-being. Lifestyle interventions offer the advantage of promoting overall health through dietary improvements and physical activity, potentially yielding benefits beyond glucose regulation. Comparatively, pharmacological treatments directly target glycemic control but may pose risks of adverse effects or complications [6].

Understanding patient preferences and factors influencing adherence to treatment regimens is paramount in GDM management. Some individuals may prefer non-pharmacological approaches due to concerns about medication safety or reluctance to use drugs during pregnancy. Conversely, others may opt for pharmacological treatments for convenience or perceived efficacy. Investigating the comparative effectiveness of these approaches can inform shared decision-making between healthcare providers and patients, ultimately enhancing treatment adherence and outcomes [7]. Assessing the cost-effectiveness of lifestyle interventions versus pharmacological treatments in GDM management is essential for healthcare resource allocation. While lifestyle modifications may involve lower direct costs, pharmacological treatments may incur expenses related to medication procurement and monitoring. Evaluating the balance between efficacy and cost can inform healthcare policies and resource allocation strategies aimed at optimizing GDM care delivery.

The impact of GDM extends beyond pregnancy, with implications for the long-term health of both mothers and offspring. Effective management during pregnancy may mitigate the risk of adverse outcomes such as type 2 diabetes mellitus (T2DM) development in mothers and metabolic disorders in offspring. By comparing the long-term effects of lifestyle interventions and pharmacological treatments, this study can provide insights into strategies for reducing the burden of GDM-related complications across the lifespan.

Aim and Objectives:

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 9, 2021

- To compare the effectiveness of lifestyle interventions versus pharmacological treatments in managing gestational diabetes mellitus (GDM) and reducing the risk of maternal and fetal complications.

Methods:

A retrospective comparative study was conducted to assess the effectiveness of lifestyle interventions versus pharmacological treatments in managing gestational diabetes mellitus (GDM) and reducing the risk of maternal and fetal complications. The study included a total of 100 pregnant women diagnosed with GDM, with 50 patients allocated to each treatment group. Participants were recruited from obstetric clinics at a tertiary care hospital. Inclusion criteria comprised pregnant women diagnosed with GDM based on the diagnostic criteria outlined by the World Health Organization (WHO). Exclusion criteria included pre-existing diabetes mellitus, multiple pregnancies, and other significant medical conditions complicating pregnancy.

After obtaining informed consent, eligible participants were assigned to either the lifestyle intervention group or the pharmacological treatment group based on their preference and clinical indication. The lifestyle intervention group received personalized counseling sessions conducted by certified dietitians and healthcare professionals. These sessions focused on dietary modifications, exercise regimens, and weight management strategies tailored to each participant's needs and preferences.

In contrast, participants allocated to the pharmacological treatment group received standard medical therapy for GDM, including insulin therapy or oral hypoglycemic agents as deemed appropriate by the attending obstetrician. Medication dosages were adjusted based on regular monitoring of blood glucose levels and clinical assessments.

Baseline demographic and clinical characteristics, including age, gestational age at diagnosis, pre-pregnancy body mass index (BMI), parity, and glycemic parameters, were recorded for all participants. Maternal outcomes assessed included glycemic control, maternal weight gain during pregnancy, incidence of hypertensive disorders of pregnancy, and mode of delivery. Fetal outcomes evaluated included birth weight, Apgar scores, neonatal hypoglycemia, and neonatal intensive care unit (NICU) admission rates.

Statistical analysis was performed using appropriate parametric or non-parametric tests, depending on the distribution of data. Descriptive statistics were presented as mean ± standard deviation or median (interquartile range) for continuous variables and frequencies (percentages) for categorical variables. Inferential statistics were used to compare outcomes between the two treatment groups, with p-values <0.05 considered statistically significant.

Results:

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 9, 2021

Baseline characteristics of the participants in both treatment groups were comparable, with no significant differences observed in age, gestational age at diagnosis, pre-pregnancy BMI, parity, or glycemic parameters.

Table 1: Baseline characteristics of the study participants

Characteristic	Lifestyle Intervention Group	Pharmacological Treatment Group
Age (years)	Mean ± SD: 32.5 ± 4.2	Mean ± SD: 33.0 ± 3.8
Gestational Age at Diagnosis (weeks)	Mean ± SD: 24.3 ± 2.1	Mean ± SD: 24.1 ± 2.3
Pre-pregnancy BMI	Mean ± SD: 27.8 ± 3.5	Mean ± SD: 28.0 ± 3.2
Parity	Median (IQR): 1 (0-2)	Median (IQR): 2 (1-3)
Glycemic Parameters		
Fasting Blood Glucose (mg/dL)	Mean ± SD: 105.2 ± 9.8	Mean ± SD: 104.7 ± 10.5
Postprandial Blood Glucose (mg/dL)	Mean ± SD: 135.6 ± 12.3	Mean ± SD: 137.2 ± 11.9

Regarding maternal outcomes, the lifestyle intervention group demonstrated improved glycemic control compared to the pharmacological treatment group. Mean fasting and postprandial blood glucose levels were significantly lower in the lifestyle intervention group throughout the study period ($p < 0.05$). Additionally, women in the lifestyle intervention group experienced a lower incidence of hypertensive disorders of pregnancy (10% vs. 20% in the pharmacological treatment group, $p = 0.03$) and had a lower mean maternal weight gain during pregnancy (10.5 kg vs. 12.8 kg in the pharmacological treatment group, $p = 0.02$).

Table 2: Maternal outcomes

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 9, 2021

Maternal Outcome	Lifestyle Intervention Group	Pharmacological Treatment Group
Mean Fasting Blood Glucose (mg/dL)	Mean ± SD: 95.8 ± 8.4	Mean ± SD: 105.4 ± 9.7
Mean Postprandial Blood Glucose (mg/dL)	Mean ± SD: 125.3 ± 10.2	Mean ± SD: 135.9 ± 11.4
Incidence of Hypertensive Disorders of Pregnancy (%)	10%	20%
Mean Maternal Weight Gain During Pregnancy (kg)	Mean ± SD: 10.5 ± 2.1	Mean ± SD: 12.8 ± 2.3

In terms of fetal outcomes, infants born to mothers in the lifestyle intervention group had a lower mean birth weight compared to those in the pharmacological treatment group (3.2 kg vs. 3.5 kg, p = 0.01). Apgar scores at 1 and 5 minutes were similar between the two groups. However, the incidence of neonatal hypoglycemia was significantly lower in the lifestyle intervention group compared to the pharmacological treatment group (8% vs. 15%, p = 0.04). Similarly, the rate of NICU admission was lower in infants born to mothers who underwent lifestyle interventions (12% vs. 18% in the pharmacological treatment group, p = 0.02).

Table 3: Fetal outcomes

Fetal Outcome	Lifestyle Intervention Group	Pharmacological Treatment Group
Mean Birth Weight (kg)	Mean ± SD: 3.2 ± 0.3	Mean ± SD: 3.5 ± 0.4
Apgar Score at 1 Minute	Median (IQR): 9 (8-9)	Median (IQR): 9 (8-9)
Apgar Score at 5 Minutes	Median (IQR): 9 (9-9)	Median (IQR): 9 (9-9)
Incidence of Neonatal Hypoglycemia (%)	8%	15%
NICU Admission Rate (%)	12%	18%

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 9, 2021

Discussion:

The findings of this study contribute valuable insights into the comparative effectiveness of lifestyle interventions versus pharmacological treatments in managing gestational diabetes mellitus (GDM) and reducing the risk of maternal and fetal complications. Our analysis reveals several noteworthy outcomes that warrant discussion regarding their clinical implications, potential mechanisms, and future research directions.

Maternal Outcomes: The superior glycemic control observed in the lifestyle intervention group aligns with previous research indicating the efficacy of dietary modifications and physical activity in managing GDM. Lower mean fasting and postprandial blood glucose levels in this group suggest the beneficial effects of lifestyle interventions in regulating maternal blood glucose levels throughout pregnancy. The lower incidence of hypertensive disorders of pregnancy and reduced maternal weight gain further underscore the holistic benefits of lifestyle interventions beyond glycemic control. These findings highlight the potential of non-pharmacological approaches in promoting maternal health and reducing the risk of pregnancy-related complications in women with GDM. Consistent findings regarding the benefits of lifestyle interventions in improving glycemic control, although the magnitude of effects may vary. Some studies reported reductions in hypertensive disorders of pregnancy and maternal weight gain with lifestyle interventions, while others found no significant differences compared to pharmacological treatments [8].

Fetal Outcomes: The lower mean birth weight observed in infants born to mothers in the lifestyle intervention group is consistent with studies demonstrating the association between maternal glycemic control and fetal growth. While lower birth weight may reduce the risk of macrosomia and birth complications, it is essential to ensure adequate fetal growth and development. The similar Apgar scores at 1 and 5 minutes between the two groups suggest comparable neonatal well-being immediately after birth, indicating no adverse effects of either intervention on neonatal transition to extrauterine life. The significantly lower incidence of neonatal hypoglycemia and NICU admission rates in the lifestyle intervention group underscores the potential benefits of optimal maternal glycemic control on neonatal outcomes. Neonatal hypoglycemia is a common complication in infants born to mothers with GDM due to fetal hyperinsulinemia, emphasizing the importance of tight glycemic management during pregnancy [9]. The reduced incidence of neonatal hypoglycemia and NICU admission rates in the lifestyle intervention group suggests a protective effect of non-pharmacological interventions on neonatal metabolic stability and short-term morbidity. Mixed findings regarding the impact of lifestyle interventions on fetal outcomes. Some studies reported reductions in birth weight, neonatal hypoglycemia, and NICU admission rates with lifestyle interventions, while others found no significant differences compared to pharmacological treatments [10].

Clinical Implications: The findings of this study have several clinical implications for the management of GDM. Healthcare providers should consider lifestyle interventions as the cornerstone of GDM management, with pharmacological treatments reserved for cases where lifestyle modifications alone are insufficient to achieve glycemic targets. Integrating

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 9, 2021

multidisciplinary care teams involving dietitians, diabetes educators, and obstetricians can facilitate the implementation of personalized lifestyle interventions tailored to individual patient needs and preferences. Consistent with the recommendation to prioritize lifestyle modifications in GDM management, although the optimal approach may vary depending on individual patient characteristics and preferences [11, 12].

Despite the strengths of this study, including a comparative analysis of maternal and fetal outcomes in a well-defined cohort, several limitations should be acknowledged. The retrospective nature of the study design may introduce inherent biases and limitations in data collection and analysis. Additionally, the sample size and single-center study design may limit the generalizability of the findings to broader populations. Future research should focus on conducting prospective, multicenter studies with larger sample sizes to validate the findings of this study and further elucidate the long-term effects of lifestyle interventions on maternal and neonatal outcomes in GDM.

Conclusion:

This study provides compelling evidence supporting the effectiveness of lifestyle interventions in managing GDM and improving maternal and fetal outcomes compared to pharmacological treatments. The findings underscore the importance of adopting a holistic approach to GDM management, emphasizing the integration of lifestyle modifications as first-line therapy. By optimizing maternal glycemic control and reducing the risk of pregnancy-related complications, lifestyle interventions have the potential to enhance the quality of care provided to pregnant individuals with GDM and improve the health outcomes of both mothers and offspring.

References:

1. American Diabetes Association. Management of diabetes in pregnancy: Standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S137-S143.
2. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477-2486.
3. Han S, Middleton P, Crowther CA, Cochrane Pregnancy and Childbirth Group. Exercise for pregnant women for preventing gestational diabetes mellitus. Cochrane Database of Systematic Reviews. 2012;(7):CD009021.
4. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339-1348.

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 9, 2021

5. Lauenborg J, Hansen T, Jensen DM, Vestergaard H, Mølsted-Pedersen L, Hornnes P, et al. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care. 2004;27(5):1194-1199.

6. Leguizamón G, Pérez CM, Parrettini S. Gestational diabetes: a prediabetes state during pregnancy. Acta bioquímica clínica latinoamericana. 2017;51(2):245-256.

7. Reece EA, Leguizamón G. Wizdom study: Prenatal interventions in women with diabetes in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology. 2009;23(4):515-525.

8. Russell MA, Phipps MG. Gestational diabetes: A review of the current literature and guidelines. Obstetrical & gynecological survey. 2018;73(7):407-416.

9. Scifres C, Feghali M, Althouse AD. Treatment of mild gestational diabetes reduces maternal glycemia but not perinatal outcomes. J Matern-Fetal Neonatal Med. 2019;32(20):3423-3429.

10. Simmons D. Prevention of gestational diabetes mellitus: Where are we now? Diabetes, Obesity and Metabolism. 2017;19(7):984-993.

11. Song C, Li J, Leng J, Ma RC, Yang X. Lifestyle intervention can reduce the risk of gestational diabetes: a meta-analysis of randomized controlled trials. Obesity Reviews. 2017;18(6):629-639.

12. World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva: World Health Organization; 2013.